BB Biotech AG

BB Biotech is a Swiss-based listed investment company specializing in focused, long-term investments in innovative biotechnology firms worldwide. The company maintains a concentrated portfolio of 20 to 35 carefully selected biotechnology companies, primarily listed on stock exchanges in the United States and Western Europe. BB Biotech targets biotech innovators developing differentiated therapies addressing significant unmet medical needs across disease areas including oncology, orphan diseases, neurological disorders, cardiovascular diseases, autoimmune conditions, and infectious diseases. The portfolio emphasizes companies leveraging advanced technologies such as RNA platforms, gene therapy, cell therapy, and small molecule and biologics development. Managed by Bellevue Asset Management, BB Biotech combines deep scientific expertise with disciplined capital allocation and active risk management to support long-term medical and economic value creation. Shares are listed on the SIX Swiss Exchange and the Frankfurt Stock Exchange, making it accessible to investors seeking exposure to the biotechnology sector through a professionally managed vehicle with permanent capital and a defined dividend policy.